KCR Expands in UK & Germany and Moves on to France
KCR has opened new offices in London and Berlin, and is now turning its attention to France.
KCR, the CRO operating in 18 countries in Europe as well as the US, has opened new offices in London and Berlin, and is now turning its attention to France.
“I am very excited seeing KCR strengthening its visibility across Western Europe, particularly in the UK and Germany, where we have already been enjoying partnerships with locally based or represented companies,” says Mike Jagielski, CEO of KCR. “Having our own entities registered in these countries will make our collaboration even stronger. It will also equip KCR with local law benefits and make our business cooperation easier. The next country we will aim for is France.”
KCR has operated in Central and Eastern Europe and the Commonwealth of Independent States since 1997. Having a local team in each of the offices gives the company insight into local regulations, and has also helped to build extensive relationships with key opinion leaders and principal investigators, according to the CRO.
KCR offers three types of professional contract research services: clinical development services, functional service provision and post-marketing clinical services, in a wide spectrum of therapeutic areas.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
